Adjuvant capecitabine in combination with docetaxel and cyclophosphamide versus anthracycline plus docetaxel and cyclophosphamide regimen in women with high-risk, HER2-negative breast cancer: An open-label, randomized controlled trial [0.03%]
卡培他滨联合多西他赛和环磷酰胺与蒽环类药物联合多西他赛和环磷酰胺新辅助治疗高危HER2阴性乳腺癌患者的开放标签、随机对照研究
Yu Song,Yingjiao Wang,Xi Cao et al.
Yu Song et al.
Background: The standard adjuvant chemotherapy for early-stage, high-risk breast cancer includes anthracyclines and taxanes. While anthracycline-based regimens have proven effective in human epidermal growth factor recept...
Associations of body mass index and waist circumference with incidence of overall and of 27 site-specific cancers: a population-based retrospective cohort study [0.03%]
体重指数和腰围与总体及27种部位特异性癌症发病风险的关联：基于人群的回顾性队列研究
Seonghye Kim,Bongseong Kim,Kyu-Won Jung et al.
Seonghye Kim et al.
Background: Overweight and obesity are known risk factors for cancer. The aim of this study was to investigate associations of body mass index (BMI) and waist circumference (WC) with incidence of 27 site-specific cancers ...
Simvastatin overcomes the pPCK1-pLDHA-SPRINGlac axis-mediated ferroptosis and chemo-immunotherapy resistance in AKT-hyperactivated intrahepatic cholangiocarcinoma [0.03%]
辛伐他汀克服AKT高活化的肝内胆管癌中铁死亡和化疗免疫治疗的耐药性中的pPCK1-pLDHA-SPRINGlac轴介导的铁死亡和化疗免疫治疗抵抗
Jinghan Zhu,Yixiao Xiong,Yuxin Zhang et al.
Jinghan Zhu et al.
Background: Intrahepatic cholangiocarcinoma (ICC) is a challenging cancer with an increasing incidence. The Phase III TOPAZ-1/KEYNOTE-966 study demonstrated chemo-immunotherapy (CIT) as a significant advancement, potentia...
First-line serplulimab plus chemotherapy in extensive-stage small-cell lung cancer: Updated results and biomarker analysis from the ASTRUM-005 randomized clinical trial [0.03%]
杜韦利西布联合化疗治疗广泛期小细胞肺癌：ASTRUM-005随机临床试验的更新结果和生物标志物分析
Ying Cheng,Shuang Zhang,Liang Han et al.
Ying Cheng et al.
Background: The ASTRUM-005 study previously demonstrated a significant overall survival (OS) benefit with serplulimab (a programmed death 1 inhibitor) plus chemotherapy versus chemotherapy alone in previously untreated ex...
Lipid metabolism reprograming by SREBP1-PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy [0.03%]
靶向SREBP1-PCSK9重构脂质代谢使胰腺癌免疫化疗增敏
Mengyi Lao,Xiaozhen Zhang,Zejun Li et al.
Mengyi Lao et al.
Background: Pancreatic cancer's aberrant lipid metabolism fuels cell growth, invasion, and metastasis, yet its impact on immune surveillance and immunotherapy is unclear. This study investigated how sterol regulatory elem...
Cell-free DNA blood-based test compared to fecal immunochemical test for colorectal cancer screening [0.03%]
血液游离DNA检测与粪便免疫化学法在结直肠癌筛查中的对比研究
Teresa Seum,Michael Hoffmeister,Hermann Brenner
Teresa Seum
A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort [0.03%]
篮子试验：双重抗CTLA-4和抗PD-1阻断在罕见肿瘤(DART)SWOG S1609中的二期临床试验结果——卵巢_hypercalcemia型小细胞癌队列中持久的应答及延迟假进展现象
Young Kwang Chae,Megan Othus,Sandip Pravin Patel et al.
Young Kwang Chae et al.
Background: The combined use of anti-programmed cell death protein 1 (PD-1)/anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) checkpoint inhibitors has been effective in various cancer types. The Southwest Oncolog...
Evaluation of exposure-response-safety relationship of model-informed low-dose 500 mg abiraterone acetate in prostate cancer patients [0.03%]
基于模型的醋酸阿比特龙（500毫克）前列腺癌患者低剂量暴露-反应-安全性关系评估
Edmund Chiong,Ziteng Wang,Eleanor Jing Yi Cheong et al.
Edmund Chiong et al.
Targeted reactivation of the novel tumor suppressor DAPK1, an upstream regulator of p53, in high-grade serous ovarian cancer by mRNA liposomes reduces viability and enhances drug sensitivity in preclinical models [0.03%]
新型肿瘤抑制因子DAPK1是一种介导p53的上游调节因子，用于在高级别浆液性卵巢癌中通过mRNA脂质体靶向激活DAPK1可降低细胞活力并增强对药物敏感性（基于前期模型）
Monika Raab,Balázs Győrffy,Samuel Peña-Llopis et al.
Monika Raab et al.
N6-methyladenosine-regulated exosome biogenesis orchestrates an immunosuppressive pre-metastatic niche in gastric cancer peritoneal metastasis [0.03%]
胃癌腹膜转移中N6-甲基腺苷调节的外泌体生成调控免疫抑制性前转移生态位
Song Li,Jianyuan Zhou,Shuang Wang et al.
Song Li et al.
Background: Gastric cancer peritoneal metastasis is clinically challenging, given the limited treatment options and poor prognosis. The molecular mechanisms that precede gastric cancer peritoneal metastasis, known as the ...